Quantitative measures detect sensory and motor impairments in multiple sclerosis

https://doi.org/10.1016/j.jns.2011.03.003Get rights and content

Abstract

Background

Sensory and motor dysfunction in multiple sclerosis (MS) is often assessed with rating scales which rely heavily on clinical judgment. Quantitative devices may be more precise than rating scales.

Objective

To quantify lower extremity sensorimotor measures in individuals with MS, evaluate the extent to which they can detect functional systems impairments, and determine their relationship to global disability measures.

Methods

We tested 145 MS subjects and 58 controls. Vibration thresholds were quantified using a Vibratron-II device. Strength was quantified by a hand-held dynamometer. We also recorded Expanded Disability Status Scale (EDSS) and Timed 25-Foot Walk (T25FW). t-tests and Wilcoxon-rank sum were used to compare group data. Spearman correlations were used to assess relationships between each measure. We also used a step-wise linear regression model to determine how much the quantitative measures explain the variance in the respective functional systems scores (FSS).

Results

EDSS scores ranged from 0–7.5, mean disease duration was 10.4 ± 9.6 years, and 66% were female. In relapsing-remitting MS, but not progressive MS, poorer vibration sensation correlated with a worse EDSS score, whereas progressive groups' ankle/hip strength changed significantly with EDSS progression. Interestingly, not only did sensorimotor measures significantly correlate with global disability measures (i.e., EDSS), but they had improved sensitivity, as they detected impairments in up to 32% of MS subjects with normal sensory and pyramidal FSS.

Conclusions

Sensory and motor deficits in MS can be quantified using clinically accessible tools and distinguish differences among MS subtypes. We show that quantitative sensorimotor measures are more sensitive than FSS from the EDSS. These tools have the potential to be used as clinical outcome measures in practice and for future MS clinical trials of neurorehabilitative and neuroreparative interventions.

Introduction

Multiple sclerosis (MS) is a complex and clinically heterogeneous disease of the central nervous system that often results in marked disability. The lesions that occur in MS can cause many neurological deficits, depending on their location and extent [1]. Common deficits include impairments of sensation, pyramidal tract dysfunction, and gait abnormalities. Evaluating MS disability has consistently relied on rating scales such as the Expanded Disability Status Scale (EDSS) [2], the Scripps Neurologic Rating Scale [3], the 12-item MS Walking Scale [4], and the Ambulation index [5]. These rating scales provide a good overall assessment of an individual's functional status; however, it is well-known that they are insensitive to subtle abnormalities and provide limited information about which impairments may be specifically contributing to an individual's loss of function [1], [6], [7]. Clinical rehabilitation studies could gain both statistical power and meaning from the use of more specific outcome measures that are sensitive to subtle neurological impairments [6], [7].

Quantitative functional testing devices such as the Vibratron II (for vibration sensation) and the hand-held dynamometer (for strength) have been used to evaluate impairments in sensation and strength for various neurological conditions including adrenomyeloneuropathy, cerebral palsy, traumatic brain injury, and peripheral neuropathy [8], [9], [10], [11], [12], [13], [14]. These devices are clinically accessible and have the potential for systematically quantifying specific impairments in MS; however, this has not been investigated. Using the same devices in a previous study, we found that impairments in vibration sensation and strength were significantly correlated with column-specific abnormalities in the spinal cord of MS subjects [15], [16]. What remains unclear is whether these tools can reliably differentiate MS impairments from controls, distinguish impairments between MS subtypes, and whether they are as sensitive or more sensitive than categorical rating scales in detecting impairments.

We hypothesized that the Vibratron II and the hand-held dynamometer are able to detect abnormalities of sensory and motor impairments in a heterogeneous group of MS patients and that they are more precise than their respective sensory and pyramidal functional system scores (FSS) of the EDSS (i.e., a global measures of disability in MS). The primary objectives of this study were to: 1) obtain baseline reference values for lower extremity quantitative sensorimotor measures in MS subjects, 2) examine whether these quantitative measures detect differences between MS subjects and matched controls, 3) compare these measures between MS subtypes, 4) evaluate the extent to which these measures correlate with global disability measures such as the EDSS and 5) evaluate their sensitivity compared to their respective EDSS FSS. This study provides the framework to begin validating the use and reliability of the Vibratron II and hand-held dynamometer as relevant MS clinical biomarkers of sensory and motor impairment.

Section snippets

Participants

Participants were recruited by convenience sampling from the Johns Hopkins MS Center from November 2004 to July 2009. Participants were excluded if they had an MS relapse within three months of testing or reported a history of peripheral neuropathy. All participants provided signed, informed consent in accordance with Institutional Review Board regulations at Johns Hopkins University and Kennedy Krieger Institute.

To address our study objectives we examined 145 individuals with MS using

Study population

In the cohort of 145 MS subjects, there was a mean age of 43.6 ± 11.9 years (mean ± SD) (range: 20–67), mean disease duration of 10.4 ± 9.6 years (range: 1–44), and 66% were females. Our MS subjects represented a wide range of disease disability (EDSS: 0–7.5) and their characteristics divided by disease subtype are presented in Table 1. Table 2A summarizes our MS cohort's vibration sensation with raw and normalized values. Table 2B summarizes our MS cohort's strength with raw and normalized values.

Discussion

Our data show that we can validly quantify lower extremity vibration sensation and strength in individuals with MS using clinically accessible tools and that these tools can detect differences among MS subtypes (i.e., RRMS, SPMS, and PPMS) and healthy controls. Vibration sensation and strength were significantly correlated to MS subtype and we found significant differences that were dependent on disease duration. Overall, all MS subtypes had significantly worse vibration sensation and strength

Funding

This work was supported by a Sylvia Lawry Physician Fellowship from the National Multiple Sclerosis Society (S.D.N.); NMSS Tissue Repair Grant (K.M.Z. and P.A.C.); NIH NICHD [grant number K01 HD049476] (K.M.Z.); and the Dana Foundation (K.M.Z.).

Acknowledgments

The authors would like to thank Divya Sambandan and Mike Shteyman for their assistance in collecting parts of this data and Dr. Joseph Arezzo for providing some of the Vibratron control data.

References (38)

  • S.L. Hauser et al.

    Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH

    NEJM

    (1983)
  • S.R. Schwid et al.

    Are quantitative functional measures more sensitive to worsening MS than traditional measures?

    Neurology

    (2000)
  • G.R. Cutter et al.

    Development of a multiple sclerosis functional composite as a clinical trial outcome measure

    Brain

    (1999)
  • K.M. Zackowski et al.

    Sensorimotor function and axonal integrity in adrenomyeloneuropathy

    Arch Neurol

    (2006)
  • M. Katz-Leurer et al.

    Hand-held dynamometry in children with traumatic brain injury: within-session reliability

    Pediatr Phys Ther

    (2008)
  • A.R. Berger et al.

    Prevalence of peripheral neuropathy in injection drug users

    Neurology

    (1999)
  • M.E. Shy et al.

    Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    Neurology

    (2003)
  • H. Deng et al.

    Quantitative measurements of vibration threshold in healthy adults and acrylamide workers

    Int Arch Occup Environ Health

    (1993)
  • A. Fatemi et al.

    Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy

    Neurology

    (2005)
  • Cited by (55)

    • Cognition and proprioception in persons with multiple sclerosis and healthy controls: Nascent findings

      2022, Multiple Sclerosis and Related Disorders
      Citation Excerpt :

      Proprioception is challenging to measure in the clinic environment, as there is no standardized quantitative measure. However, both proprioception and vibratory sensation are carried along the dorsal columns; thus, our lab has established quantitative vibratory sensation as a reliable and valid proxy measure of proprioception in persons with MS (Newsome et al., 2011; Fritz et al., 2019). Vibratory sensation reflects pathological differences in spatially distinct areas of the central nervous system and supplements information obtained with brain imaging measures of atrophy, particularly in persons with progressive MS (Fritz et al., 2019).

    View all citing articles on Scopus
    View full text